Literature DB >> 21203788

Insights into binding modes of 5-HT2c receptor antagonists with ligand-based and receptor-based methods.

Chunhua Lu1, Fangfang Jin, Cui Li, Weihua Li, Guixia Liu, Yun Tang.   

Abstract

5-hydroxytryptamine-2c (5-HT2c) receptor antagonists have clinical utility in the management of nervous system. In this work, ligand-based and receptor-based methods were used to investigate the binding mode of h5-HT2c receptor antagonists. First, the pharmacophore modeling of the h5-HT2c receptor antagonists was carried out by CATALYST. Then, the h5-HT2c antagonists were docked to the h5-HT2c receptor model. Subsequently, the comprehensive analysis of the pharmacophore and docking results revealed the structure-activity relationship of 5-HT2c receptor antagonists and the key residues involved in the interactions. For example, three hydrophobic points in the ligands corresponded to the region surrounded by Val135, Val208, Phe214, Ala222, Phe327, Phe328 and Val354 of the h5-HT2c receptor. The carbonyl group of compound 1 formed a hydrogen bond with Asn331. The nitrogen atom in the piperidine of compound 1 corresponding to the positive ionizable position of the best pharmacophore formed the electrostatic interactions with the carbonyl of Asp134, Asn331 and Val354, and with the hydroxyl group of Ser334. In addition, a predictive CoMFA model was developed based on the 24 compounds that were used as the training set in the pharmacophore modeling. Our results were not only useful to explore the detailed mechanism of the interactions between the h5-HT2c receptor and antagonists, but also provided suggestions in the discovery of novel 5-HT2c receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21203788     DOI: 10.1007/s00894-010-0936-9

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  26 in total

1.  RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist.

Authors:  D W Bonhaus; K K Weinhardt; M Taylor; A DeSouza; P M McNeeley; K Szczepanski; D J Fontana; J Trinh; C L Rocha; M W Dawson; L A Flippin; R M Eglen
Journal:  Neuropharmacology       Date:  1997 Apr-May       Impact factor: 5.250

2.  5-HT2C antagonists based on fused heterotricyclic templates: design, synthesis and biological evaluation.

Authors:  Dieter Hamprecht; Fabrizio Micheli; Giovanna Tedesco; Daniele Donati; Marcella Petrone; Silvia Terreni; Martyn Wood
Journal:  Bioorg Med Chem Lett       Date:  2006-10-17       Impact factor: 2.823

3.  Studies towards the identification of a new generation of atypical antipsychotic agents.

Authors:  Vincenzo Garzya; Ian T Forbes; Andrew D Gribble; Mike S Hadley; Andrew P Lightfoot; Andrew H Payne; Alexander B Smith; Sara E Douglas; David G Cooper; Ian G Stansfield; Malcom Meeson; Emma E Dodds; Declan N C Jones; Martyn Wood; Charlie Reavill; Carol A Scorer; Angela Worby; Graham Riley; Peter Eddershaw; Chris Ioannou; Daniele Donati; Jim J Hagan; Emiliangelo A Ratti
Journal:  Bioorg Med Chem Lett       Date:  2006-10-19       Impact factor: 2.823

4.  Synthesis and structure-activity relationship of 1H-indole-3-carboxylic acid pyridine-3-ylamides: a novel series of 5-HT2C receptor antagonists.

Authors:  Chul Min Park; So Young Kim; Woo Kyu Park; No Sang Park; Churl Min Seong
Journal:  Bioorg Med Chem Lett       Date:  2008-06-21       Impact factor: 2.823

Review 5.  Drugs in development for the treatment of schizophrenia.

Authors:  Robin Emsley
Journal:  Expert Opin Investig Drugs       Date:  2009-08       Impact factor: 6.206

Review 6.  Three-dimensional pharmacophore methods in drug discovery.

Authors:  Andrew R Leach; Valerie J Gillet; Richard A Lewis; Robin Taylor
Journal:  J Med Chem       Date:  2010-01-28       Impact factor: 7.446

7.  A series of bisaryl imidazolidin-2-ones has shown to be selective and orally active 5-HT2C receptor antagonists.

Authors:  Caroline J Goodacre; Steven M Bromidge; David Clapham; Frank D King; Peter J Lovell; Mike Allen; Lorraine P Campbell; Vicky Holland; Graham J Riley; Kathryn R Starr; Brenda K Trail; Martyn D Wood
Journal:  Bioorg Med Chem Lett       Date:  2005-11-15       Impact factor: 2.823

8.  Isoindolone derivatives, a new class of 5-HT2C antagonists: synthesis and biological evaluation.

Authors:  Dieter Hamprecht; Fabrizio Micheli; Giovanna Tedesco; Anna Checchia; Daniele Donati; Marcella Petrone; Silvia Terreni; Martyn Wood
Journal:  Bioorg Med Chem Lett       Date:  2006-10-17       Impact factor: 2.823

9.  Molecular cloning and expression of an adenosine A2b receptor from human brain.

Authors:  K D Pierce; T J Furlong; L A Selbie; J Shine
Journal:  Biochem Biophys Res Commun       Date:  1992-08-31       Impact factor: 3.575

Review 10.  Agomelatine: a novel mechanism of antidepressant action involving the melatonergic and the serotonergic system.

Authors:  Luis San; Belen Arranz
Journal:  Eur Psychiatry       Date:  2008-06-25       Impact factor: 5.361

View more
  3 in total

1.  In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.

Authors:  Guanglin Kuang; Guoping Hu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-09       Impact factor: 1.810

2.  In Silico Studies Targeting G-protein Coupled Receptors for Drug Research Against Parkinson's Disease.

Authors:  Agostinho Lemos; Rita Melo; Antonio Jose Preto; Jose Guilherme Almeida; Irina Sousa Moreira; Maria Natalia Dias Soeiro Cordeiro
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

3.  Similarities between the Binding Sites of SB-206553 at Serotonin Type 2 and Alpha7 Acetylcholine Nicotinic Receptors: Rationale for Its Polypharmacological Profile.

Authors:  Patricia Möller-Acuña; J Sebastián Contreras-Riquelme; Cecilia Rojas-Fuentes; Gabriel Nuñez-Vivanco; Jans Alzate-Morales; Patricio Iturriaga-Vásquez; Hugo R Arias; Miguel Reyes-Parada
Journal:  PLoS One       Date:  2015-08-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.